|Bid||4.2200 x 36100|
|Ask||0.0000 x 317000|
|Day's Range||4.2500 - 4.2600|
|52 Week Range||0.7800 - 4.3000|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.28|
NEW YORK, NY / ACCESSWIRE / September 10, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in ...
NEW YORK, NY / ACCESSWIRE / August 16, 2019 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cambrex Corporation (NYSE:CBM) The investigation ...
WILMINGTON, Del., Aug. 15, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Wesco Aircraft Holdings, Inc. (NYSE: WAIR) regarding possible breaches of.
KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (email@example.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-cvrs/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Under the terms of the transaction, each share of Genomic common stock will be converted into the right to receive $27.50 in cash and $44.50 in shares of Exact Sciences for each share of Genomic common stock owned. Under the terms of the agreement, each share of Navigant common stock will be converted into the right to receive $28.00 in cash for each share of Navigant common stock owned.
NEW YORK, Aug. 09, 2019 -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Gannett Co., Inc. (NYSE: GCI)The.
WILMINGTON, Del., Aug. 09, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Gannett Co., Inc. (NYSE: GCI) regarding possible breaches of fiduciary.
NEW YORK , Aug. 8, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Corindus Vascular Robotics, Inc. (NYSE: CVRS) on behalf of Corindus ...
NEW YORK , Aug. 8, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Corindus Vascular Robotics, Inc. ("Corindus" ...
NEW YORK, Aug. 08, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Corindus Vascular Robotics, Inc..
WILMINGTON, DE / ACCESSWIRE / August 8, 2019 / Rigrodsky & Long, P.A.: Do you own shares of Corindus Vascular Robotics, Inc. (NYSE AMERICAN: CVRS )? Did you purchase any of your shares prior to August ...
NEW YORK, Aug. 08, 2019 -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Corindus Vascular Robotics, Inc. (NYSE AMERICAN: CVRS) to.
Corindus Vascular (CVRS) delivered earnings and revenue surprises of -20.00% and 11.59%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Corindus announced today a definitive agreement to be acquired by Siemens Healthineers for approximately $1.1 billion, or $4.28 per share, in an all-cash transaction
Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, a German stock listed company, will acquire all issued and outstanding shares of common stock of Corindus for $4.28 per share in cash, representing an aggregate purchase price of approximately $1.1 billion. “We are pleased to have reached this agreement with Siemens Healthineers,” said Mark J. Toland, President and Chief Executive Officer of Corindus.
Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer,
Corindus Vascular (CVRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mark Toland became the CEO of Corindus Vascular Robotics, Inc. (NYSEMKT:CVRS) in 2016. This report will, first...